Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model

J Neurol. 2004 Sep;251(9):1080-4. doi: 10.1007/s00415-004-0481-5.


Rasagiline is an antiapoptotic compound with neuroprotective potential. We examined its neuroprotective effect alone and in combination with the putative glutamate release blocker riluzole in the G93A model of familial amyotrophic lateral sclerosis (fALS). Endpoints of experimental treatment were survival and motor activity. The drug had a significant dose-dependent therapeutic effect on both preclinical and clinical motor function and survival of the animals. We also found that the combination of rasagiline with riluzole is safe and increases survival by about 20 % in a dose-dependent manner. Therefore, we conclude that the combination of rasagiline and riluzole is a promising clinical combination for the improvement of current neuroprotective treatment strategies of ALS.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Amyotrophic Lateral Sclerosis / enzymology
  • Amyotrophic Lateral Sclerosis / genetics
  • Animals
  • Disease Models, Animal*
  • Drug Therapy, Combination
  • Humans
  • Indans / therapeutic use*
  • Mice
  • Mice, Transgenic
  • Riluzole / therapeutic use*
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase-1
  • Survival Rate


  • Indans
  • SOD1 protein, human
  • rasagiline
  • Riluzole
  • Sod1 protein, mouse
  • Superoxide Dismutase
  • Superoxide Dismutase-1